The MCRN portfolio has grown substantially, from an almost non-existent base, to a position where there are currently > 250 high quality studies of medicines for children that are supported by the network. The portfolio is diverse yet balanced, complex and relevant to the needs of children.
The development of the MCRN portfolio is assured by the active involvement of the 14 CSGs, whose remit it is to prioritise and develop the future medicines for children portfolio of research, and also to support others in the development of new studies.
The majority of the studies within the portfolio are RCTs. We also have a proportion of cohort studies within the portfolio, some of which address pharmacovigilance. A number of the qualitative studies concern perceptions around undertaking, or participating in randomised controlled trials of medicines for children. Others are investigating factors relating to the prescribing and taking of medicines.
Studies that have been adopted/included by the MCRN can be searched and viewed by clicking here.